Back to results
US 8,067,011 B2Granted
Compositions and methods for treating B-cell malignancies
AssigneeChimeros, Inc.
InventorsClaude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
Life of this patent
Estimating the term…
Abstract
The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.
Claims28
A targeted multi-layered drug delivery system comprising:
- a) a first layer comprising a nanocage made by self-assembly of a plurality of Hepatitis B Virus (HBV) core protein;
- b) a second layer comprising a lipid bi-layer made by self-assembly of a plurality of anionic or cationic lipids, wherein the lipid bi-layer is covalently attached to the nanocage;
- c) a B-cell targeting moiety anchored into the lipid bi-layer;
- and
- d) at least one synthetic inhibitory RNA molecule encapsulated in the nanocage.
2 more elements
A targeted multi-layered drug delivery system comprising:
- (a) a first layer comprising a nanocage comprising a plurality of modified Hepatitis B Virus (HBV) core protein;
- (b) a second layer comprising a lipid bi-layer comprising a plurality of anionic or cationic lipids, wherein the lipid bi-layer is covalently attached to said first layer through a maleimide intermediate;
- (c) a B-cell targeting moiety anchored to the lipid bi-layer;
- and
- (d) at least one synthetic inhibitory RNA molecule encapsulated in the nanocage.
2 more elements
A targeted multi-layered drug delivery system comprising:
- (a) a first layer comprising a nanocage comprising a plurality of modified Hepatitis B Virus (HBV) core protein comprising the amino acid sequence of SEQ ID NO:
- 1, wherein the glutamic acid at amino acid 77 is changed to a cysteine;
- (b) a second layer comprising a lipid bi-layer comprising a plurality of anionic or cationic lipids, wherein the lipid bi-layer is covalently attached to said first layer by a phosphatidyl-ethanolamine maleimide to the cysteine at amino acid 77 of SEQ ID NO:
- 1;
- (c) a B-cell targeting moiety anchored to the lipid bi-layer;
- and
- (d) at least one synthetic inhibitory RNA molecule encapsulated in the nanocage.
4 more elements
Dependencies are inferred from the claim text.